1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
T cell lymphoma - Pipeline Insight, 2021

T cell lymphoma - Pipeline Insight, 2021

  • May 2021
  • 200 pages
  • ID: 6089321
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“T cell lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in T cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

T cell lymphoma Understanding

T cell lymphoma: Overview
T-cell lymphomas represent a diverse group of non-Hodgkin lymphomas of mature T-cell origin that generally are associated with unfavorable prognosis. However, recent breakthroughs have allowed a better understanding of pathogenetic mechanisms of T-cell lymphomagenesis and uncovered molecular alterations that can be assessed using new biomarker approaches and can be specifically targeted with documented improvements in outcomes. A particularly promising area in which significant progress has been made is the role of epigenetic alterations, including dysregulation of DNA methylation and histone modifications, in T-cell lymphomagenesis.
T-cell lymphomas encompass a group of heterogeneous diseases accounting for less than 10% of non-Hodgkin lymphomas. With the exception of ALK positive anaplastic large cell lymphoma, T-cell lymphomas also tend to be more clinically aggressive than their B-cell counterparts.
In spite of substantial advances in the treatment of lymphoma in general, the prognosis of patients with relapsed or treatment-refractory T-cell lymphoma remains poor, necessitating the development of novel approaches and therapies. Epigenetic dysregulation has a potential role in initiating and promoting a wide variety of malignancies and is observed in both B-cell and T-cell lymphomas.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence T cell lymphoma R&D. The therapies under development are focused on novel approaches for T cell lymphoma.

T cell lymphoma Emerging Drugs Chapters
This segment of the T cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

T cell lymphoma Emerging Drugs
• SGX-301: Soligenix
SGX301 is a photodynamic therapy using synthetically manufactured hypericin in an ointment combined with visible fluorescent light. Hypericin is one of the most photoactive compounds known – it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light, instead of UV A or UV B light, which are associated with increased cancer risks.
Synthetic hypericin, the active ingredient in SGX301, tends to accumulate in T-cells. Once the hypericin is in the T-cells, it can be activated by safe, visible fluorescent light. When synthetic hypericin is activated it creates oxygen radicals which subsequently cause cellular toxicity, killing the targeted T-cells. It is currently in Phase III stage of development for Cutaneous T-cell lymphoma and is being developed by Soligenix.
• SP-02: Solasia Pharma
SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. In a Phase II study in the U.S. Intravenous darinaparsin demonstrated evidence of clinical activity in malignant lymphoma, and in particular peripheral T-cell lymphoma (PTCL). Darinaparsin was granted Orphan Drug Designation in the U.S. and Europe as a treatment of PTCL and Solasia intends to seek similar status in Japan.
It is currently in Phase III stage of development for the treatment of peripheral T-cell lymphoma (PTCL) and is being developed by Solasia Pharma.
Further product details are provided in the report……..

T cell lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different T cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on T cell lymphoma
There are approx. 100+ key companies which are developing the T cell lymphoma. The companies which have their T cell lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Soligenix.
• Phases
This report covers around 120+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
T cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

T cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T cell lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T cell lymphoma drugs.

T cell lymphoma Report Insights
• T cell lymphoma Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

T cell lymphoma Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:
• How many companies are developing T cell lymphoma drugs?
• How many T cell lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for T cell lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the T cell lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for T cell lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Celgene
• CSPC ZhongQi Pharmaceutical Technology
• Jazz Pharmaceuticals
• Genor Biopharma
• Eisai
• Soligenix
• Elorac
• Shanghai YingLi Pharmaceutical
• ViGenCell
• Daiichi Sankyo
• Chia Tai Tianqing Pharmaceutical Group
• BeiGene
• Kura Oncology
• Solasia Pharma
• Innovent bilogics
• Nanjing Sanhome Pharmaceutical
• Rhizen Pharmaceuticals SA
• 4SC AG
• Precision Bioscience
• Millennium Pharmaceuticals, Inc.
• Innate Pharma
• ImmuneOncia Therapeutics
• HUYA Bioscience International
• CerRx, Inc.
• Shandong New Time Pharmaceutical Co., LTD
• Verastem, Inc.
• Janssen Research & Development
• Celleron Therapeutics
• CStone Pharmaceuticals
• Viridian Therapeutics
• Hebei Senlang Biotechnology Inc.
• Galderma
• Seagen
• Bioniz Therapeutics
• Almirall
• Dizal Pharmaceuticals
• Pfizer
• Hoffmann-La Roche
• Affimed GmbH
• Sorrento Therapeutics
• Merck Sharp & Dohme
• Eli Lilly and Company
• Bayer
• Genzyme
• Portola Pharmaceuticals
• Onyx Pharmaceuticals
• AstraZeneca
• Astex Therapeutics
• Yake Biotechnology Ltd.
• Aileron Therapeutics
• Akeso Pharmaceuticals, Inc.
• Viracta
• Otsuka Pharmaceutical
• VelosBio
• Trillium Therapeutics Inc.
• Mundipharma-EDO GmbH
• TG Therapeutics, Inc.
• PersonGen BioTherapeutics (Suzhou) Co
• Sorrento Therapeutics
• Oncotartis
• Myeloid Therapeutics
• Bio-Path Holdings, Inc.
• Legend Biotech
• Immune Cell
• Genzada Pharmaceuticals
• Gracell
• CRISPR Therapeutics
• Corvus Pharmaceuticals, Inc.
• Rafael Therapeutics
• Antengene Corporation
• Viridian Therapeutics
• iCell Gene Therapeutics
• Tessa Therapeutics
• Boryung Pharmaceutical Co., Ltd
• Bristol-Myers Squibb
• Antengene Corporation
• Amgen
• ADC Therapeutics S.A.
• Legend Biotech USA Inc
• VidacPharma
• Medc Biopharma
• Scopus Biopharma
• Almirall
• Brickell Bio
• AVM Biotechnology
• Autolus
• Applied Therapeutics
• TetraLogic Pharmaceuticals
• Moleculin Biotech

Key Products
• Lenalidomide
• Mitoxantrone Hydrochloride
• JZP-458
• GB226
• Denileukin diftitox
• SGX 301
• Naloxone Hydrochloride
• YY-20394
• VT-EBV-N
• Valemetostat Tosylate
• TQ-B3525
• TQ-B3101
• Tislelizumab
• Tipifarnib
• SP-02L
• SP-02
• Sintilimab
• SHC014748M
• SGN-35
• RP6530
• Resminostat
• Pembrolizumab
• PBCAR20
• Nivolumab
• MLN 9708
• Letermovir
• Lacutamab
• IPH4102
• IMC-001
• HBI-8000
• Fenretinide
• F520
• Duvelisib
• DS-3201
• Daratumumab
• CXD 101
• CS1001
• Cobomarsen
• CD7 CAR-T
• CD11301
• Brentuximab Vedotin
• BNZ132-1-40
• BNZ1
• AZD4205
• Azacytidine
• Avelumab
• Atezolizumab
• AFM13
• STI-3031
• MK-3475
• LY3039478
• Durvalumab
• Copanlisib
• Clofarabine
• Cerdulatinib (PRT062070)
• carfilzomib
• AZD5991
• ASTX660
• ALRN-6924
• AUTO4
• AK104
• Nanatinostat + Valganciclovir
• ASTX660
• ARGX-110
• VLS-101
• TTI-621
• Tinostamustine
• TGR-1202
• Temsirolimus
• Sofusa anti-PD1
• SEA-TGT
• OT-82
• MT-101
• L-Bcl-2 antisense oligonucleotide
• LB1901
• ICAR30 T cells
• GZ17-6.02
• GC027
• CTX130
• CPI-818
• CPI-613/Devimistat
• Cobomarsen
• CD4 CAR T cells
• CD30.CAR-T
• BR101801
• BMS-906024
• AZD4573
• ATG-010
• AMG 319
• ADCT-301
• LB1901
• CD7-CART
• VDA-1102
• MDC 2021
• MDC 2020
• CO-sTiRNA
• CD-7 UCART
• BNZ1
• BBI-3000
• AVM-0703
• Auto 5
• AT-104
• Lorlatinib
• CPX-351
• SHP-141
• WP1220

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on